CeriBell (NASDAQ:CBLL) Shares Gap Up – Still a Buy?

CeriBell (NASDAQ:CBLL) gapped up prior to trading on Monday . The stock had previously closed at $21.03, but opened at $22.09. CeriBell shares last traded at $21.27, with a volume of 7,158 shares changing hands.

Analysts Set New Price Targets

CBLL has been the subject of a number of research reports. TD Cowen lifted their price objective on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $32.60.

CeriBell Stock Up 0.1 %

The business has a 50 day moving average of $22.56.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. As a group, analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of CeriBell during the fourth quarter valued at $32,000. Summit Investment Advisors Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth about $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell in the fourth quarter valued at approximately $37,000. BNP Paribas Financial Markets purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in CeriBell during the fourth quarter worth approximately $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.